Findings
NASOPHARYNGEAL CANCER
In this nonrandomized controlled trial of 44 patients with locoregionally advanced nasopharyngeal cancer, the addition of bevacizumab to standard chemoradiation was not associated with excessive or unwarranted toxic effects.